^
Association details:
| Biomarker: | CLDN18.2 underexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | ATG-022 (CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1143 / 7 - ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts
Published date:
03/09/2022
Excerpt:
ATG-022 demonstrated potent in vitro and in vivo antitumor effects, with in vivo efficacy observed in CLDN18.2-low expression PDX models...
